Vurdering av immunfunksjon ved sepsis
Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the ~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Mrunmayi Tilak
- Telefonnummer: 612-624-9990
- E-post: mtilak@umn.edu
Studiesteder
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
- Rekruttering
- University of Minnesota
-
Ta kontakt med:
- Kristine Kancans
- E-post: kanca008@umn.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients with and without sepsis in the ICU, compared to healthy volunteers
Beskrivelse
ICU With Sepsis Inclusion Criteria:
-
Age ≥ 18
-
Presumed diagnosis of sepsis, defined as "patients with life-threatening organ dysfunction caused by a dysregulated host response to infection"
-
Patients in the ICU who meet 2 or more of the quick SOFA (qSOFA) definition along with organ dysfunction:
- Respiration rate ≥ 22 breaths/min and/or mechanically ventilated
- An alteration in mental status
- Systolic blood pressure of less than 100 mm Hg and/or receiving inotropes to maintain blood pressure AND/OR
- An acute change in SOFA score ≥2 points, consequent to the infection (can assume SOFA score = 0 in patients with no pre-existing organ dysfunction)
ICU Without Sepsis Inclusion Criteria:
- Age ≥ 18
- Patients requiring care at a M Health Fairview ICU due to high acuity of illness and no other evidence of sepsis
Healthy Volunteer Inclusion Criteria
- Age greater or equal to 18
- ASA status 1, 2 or 3
- May include patients who are receiving dialysis in an outpatient setting
Exclusion Criteria (all groups):
- Active cancer with chemotherapy and/or radiation treatment within the past 6 weeks
- Medication usage that includes immunosuppressive drugs, biologic agents, cytokines, growth factor and interleukins
- Steroid medication usage of > 300mg hydrocortisone per day (equivalent of > 20mg prednisone). Patients with chronic steroid use will be excluded, however patients who have had stress dose steroids administered following admission will be included.
- Patients with a history of, or who currently have evidence of autoimmune disease, including but not limited to: myasthenia gravis, Guillain Barré syndrome, systemic lupus erythematosus, multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's granulomatosis, HIV/AIDS, etc.
- Patients with active or a history of acute or chronic lymphocytic leukemia
- Known history of chronic hepatitis B (HBV) infection and not on treatment with HBV nucleoside analogues prior to the current hospitalization, or HBV DNA > 100 IU/mL
- Known history of infection with hepatitis C (HCV) and currently undergoing treatment for HCV infection or has detectable HCV RNA
- Participation in another investigational interventional drug study within the past 4 weeks
- Current pregnancy
- Current incarceration
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_CONTROL
- Tidsperspektiver: PROSPECTIVE
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Friske Frivillige
|
No intervention is included in this study |
|
ICU -pasienter med sepsis
|
No intervention is included in this study |
|
ICU -pasienter uten sepsis
|
No intervention is included in this study |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
EliSpot - Day 1
Tidsramme: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
EliSpot - Day 4
Tidsramme: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
EliSpot - Day 7
Tidsramme: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
EliSpot - Day 14
Tidsramme: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
EliSpot - Day 21
Tidsramme: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
EliSpot - Day 28
Tidsramme: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Ex Vivo TNF Production - Day 1
Tidsramme: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Ex Vivo TNF Production - Day 4
Tidsramme: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Ex Vivo TNF Production - Day 7
Tidsramme: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Ex Vivo TNF Production - Day 14
Tidsramme: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Ex Vivo TNF Production - Day 21
Tidsramme: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Ex Vivo TNF Production - Day 28
Tidsramme: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 1
Tidsramme: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 4
Tidsramme: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 7
Tidsramme: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 14
Tidsramme: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 21
Tidsramme: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 28
Tidsramme: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Quantification of Cytokines in Serum - Day 1
Tidsramme: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Quantification of Cytokines in Serum - Day 4
Tidsramme: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Quantification of Cytokines in Serum - Day 7
Tidsramme: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Quantification of Cytokines in Serum - Day 14
Tidsramme: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Quantification of Cytokines in Serum - Day 21
Tidsramme: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Quantification of Cytokines in Serum - Day 28
Tidsramme: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Quantification of Chemokines in Serum - Day 1
Tidsramme: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Quantification of Chemokines in Serum - Day 4
Tidsramme: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Quantification of Chemokines in Serum - Day 7
Tidsramme: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Quantification of Chemokines in Serum - Day 14
Tidsramme: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Quantification of Chemokines in Serum - Day 21
Tidsramme: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Quantification of Chemokines in Serum - Day 28
Tidsramme: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Transcriptional Profiling - Day 1
Tidsramme: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Transcriptional Profiling - Day 4
Tidsramme: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Transcriptional Profiling - Day 7
Tidsramme: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Transcriptional Profiling - Day 14
Tidsramme: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Transcriptional Profiling - Day 21
Tidsramme: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Transcriptional Profiling - Day 28
Tidsramme: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
CBC - Day 1
Tidsramme: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
CBC - Day 4
Tidsramme: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
CBC - Day 7
Tidsramme: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
CBC - Day 14
Tidsramme: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
CBC - Day 21
Tidsramme: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
CBC - Day 28
Tidsramme: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Thomas Griffith, PhD, University of Minnesota
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- URO-2025-34202
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .